Zimmer Holdings, Inc. Q2 2009 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2009. Zimmer Holdings, Inc. is a global leader in orthopaedic reconstructive implants, dental implants, spinal implants, trauma products, and related surgical products. The company operates through three geographic segments: Americas, Europe, and Asia Pacific. The filing reflects the impact of a weaker global economy, foreign currency fluctuations, and ongoing integration of the Abbott Spine acquisition completed in late 2008.
Key Financial Metrics
| Metric (in millions) | Q2 2009 | Q2 2008 | YTD 2009 | YTD 2008 |
|---|---|---|---|---|
| Net Sales | $1,019.9 | $1,079.5 | $2,012.5 | $2,138.7 |
| Gross Profit | $783.1 | $817.2 | $1,545.4 | $1,621.7 |
| Gross Margin | 76.8% | 75.7% | 76.8% | 75.8% |
| Operating Profit | $296.5 | $308.4 | $576.3 | $640.0 |
| Net Earnings | $210.1 | $227.1 | $412.3 | $466.4 |
| Diluted EPS | $0.98 | $0.99 | $1.88 | $2.01 |
| Cash from Operations (YTD) | $379.7 | $523.3 | $379.7 | $523.3 |
| Long-Term Debt | $653.5 | $460.1 | $653.5 | $460.1 |
| Cash and Equivalents | $277.5 | $212.6 | $277.5 | $212.6 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 6% in Q2 and 6% YTD compared to 2008. The decline was driven primarily by a 5% negative impact from foreign currency exchange rates (stronger U.S. Dollar) and lower volume due to the global economic slowdown.
- Segment Performance: Europe sales dropped 14% in Q2, heavily impacted by currency. Americas sales were relatively flat (-1%), while Asia Pacific declined 6%. Spine sales grew 18% YTD due to the Abbott Spine acquisition, while Dental sales fell 17% due to economic weakness and compliance initiatives.
- Unusual Items: The company recorded a $32.1 million gain from the curtailment and settlement of U.S. and Puerto Rico postretirement benefit plans. Conversely, "Acquisition, integration, realignment and other" expenses increased to $36.5 million in Q2 (from $12.5 million in 2008), largely due to a $16.6 million workforce realignment charge.
- Debt and Liquidity: Long-term debt increased by $193.4 million to $653.5 million, primarily to fund share repurchases. Cash and cash equivalents increased to $277.5 million.
Guidance, Outlook, and Risks
- Outlook: Management expects global selling prices to be down approximately 1% for the full year 2009. They anticipate a 3% negative impact on sales from foreign currency for the remainder of the year. R&D spending is expected to return to a historical average of 5-6% of sales.
- Disruptive Events: The company notes that customer losses from the 2008 suspension of the Durom Cup and other compliance-related disruptions have stabilized in the first half of 2009, though sales growth remains slower than the market.
- Risks and Contingencies:
- Legal Proceedings: Ongoing product liability claims related to the Durom Cup (reserve of $49.9 million) and intellectual property litigation with Howmedica Osteonics Corp.
- Government Investigations: The company is cooperating with an informal SEC investigation regarding the Foreign Corrupt Practices Act and is subject to a Corporate Integrity Agreement with the OIG-HHS through 2012.
- Healthcare Reform: Uncertainty regarding U.S. healthcare reform and potential reimbursement cuts poses a risk to future sales.
Investor Verification Checklist
- Verify the sustainability of the $32.1 million curtailment gain and its impact on normalized earnings.
- Monitor the resolution of the Durom Cup product liability claims and the adequacy of the $49.9 million reserve.
- Assess the impact of the strong U.S. Dollar on future international revenue, particularly in Europe.
- Review the progress of the Abbott Spine integration and the realization of sales synergies.
- Track the status of the SEC investigation regarding the Foreign Corrupt Practices Act.
- Confirm the company's ability to maintain liquidity given the increased debt load from share repurchases ($337.8 million YTD).